AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01435967 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Data collected when only the lyophilised formulation of Rotarix was in use (which is considered as baseline) will be specifically compared to data collected post the introduction of the liquid formulation. The results will also be compared to available vaccine coverage data for those rotavirus vaccines being used in Belgium.
Study NCT04593407 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic mucosal resection (EMR)
Description: Endoscopic mucosal resection (EMR) is an endoscopic resection technique that allows the removal of large colorectal lesions using a conventional lift-and-cut procedure or an underwater technique
Study NCT04593407 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD)
Description: Endoscopic submucosal dissection (ESD) is an endoscopic procedure that allows dissection of larger colorectal lesions in one piece using endoknives.~The procedure is technically more difficult, much more time-consuming than EMR, mandates multiday hospital admission and has an increased risk of perforation.
Study NCT01700712 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Lactobacilli reuteri
Study NCT01700712 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04157283 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI brain, visual evoked potential, Cerebrospinal Fluid, Sexual dysfunction measure, Depressive symptoms assessment and Multiple Sclerosis Quality of Life-54(MSQOL-54)
Description: 1. Neurophysiological Evaluation:~   Visual Evoked Potential (VEP).~2. Imaging Evaluation:~   Conventional MRI.~3. Cerebrospinal Fluid (CSF):~4. Sexual dysfunction measure: through the international index of erectile function (IIEF), female sexual function questionnaire (SFQ) and the sexual Quality of life male and female version (SQoL) (American Psychiatric Association, 1994).~5. Depressive symptoms assessment through The BDI (The Beck Depression Inventory) which is the most common instrument measuring the severity of depression.~6. Fatigue symptoms were evaluated through fatigue subscale of Multiple Sclerosis Quality of Life-54(MSQOL-54).
Study NCT01993563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graded Motor Imagery
Description: GMI program includes three steps: Implicit Motor Imagery (IMI); Explicit Motor Imagery (EMI) and Mirror Box Therapy (MT).~IMI included a training based on Hand Laterality Discrimination Tasks. During these tasks 60 pictures of right and left hands are projected randomly on a 15 screen. Patients are asked to choose whether the images seen are right or left and therefore to click respectively the right or the left button on a mouse.~EMI training consists in imagining a movement without actual performing it. It will be introduced during IMI's last two sessions and gradually enhanced increasing the complexity of motor skills to be imagined. The therapist shows or explains in details the movements the patient have to mentally rehearsed.~MT treatments will start with simply watching the unaffected hand in the mirror and increased toward functional movement. When possible, gentle movement with the affected hand will be encouraged behind the reflecting part of the mirror.
Study NCT01993563 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Patients will undergo to a standard treatment, that is thought to be the best option for that specific patients. In our hospital, treatment options include: motor training, functional training, occupational therapy, bilateral arm training or motor treatment using virtual reality devices.
Study NCT01026220 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Description: Given IV or SC
Study NCT00493584 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angiography / Percutaneous coronary intervention
Description: Coronary Angiography and PCI using standard protocols and guidelines. Contrast either Iomeron or Visipaque at the operators discretion. Equipment used for the PCI is determined at the operators discretion. All patients undergoing primary PCI receive 10.000 units of Heparin, 600 mg of Clopidogrel and a Glycoprotein IIb/IIIa inhibitor. Patients randomized to standard treatment receive 300 mg of Clopidogrel and 120IU/kg of Dalteparin b.i.d until revascularization. Glycoprotein IIb/IIIa inhibitors or thrombin inhibitors can be given as a supplement at the local hospital at the physicians discretion. All patients receive 300 mg of aspirin upon admission or diagnosis in the ambulance.
Study NCT01568957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gait training
Description: Twelve 30-minute sessions plus 10-minute stretching and warm up, provided 3 times per weeks for 4 weeks. Up to 6 weeks are allowed to complete the 12 sessions.
Study NCT01568957 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gait training
Description: Twelve 30-minute sessions plus 10-minute stretching and warm up, provided 3 times per weeks for 4 weeks. Up to 6 weeks are allowed to complete the 12 sessions.
Study NCT03417999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dose-escalation of atomized intranasal dexmedetomidine
Study NCT01335659 — intervention group
Intervention type: DEVICE
Intervention: Fractional flow reserve
Description: Fractional flow reserve measured by pressure wire
Study NCT01335659 — intervention group
Intervention type: DEVICE
Intervention: IVUS
Description: intravascular ultrasound~:IVUS was performed in a standard fashion using an automated motorized pullback system (0.5mm/s) with commercially available imaging catheter
Study NCT02487901 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonic osteotome
Description: making gutter with ultrasonic osteotome
Study NCT02487901 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: drill
Description: making gutter with drill
Study NCT04273620 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Optokinetic stimulation and cueing-based reading therapy (OKS-READ)
Description: Each intervention session starts with an optokinetic stimulation (OKS) of at least 15 minutes duration. A pattern of squares, dots, triangles and stars will coherently and continuously move to the left on a computer screen in front of the patients. Patients are instructed to choose one stimulus and follow it with the eyes until it has reached the left side of the screen, then jump to the right edge of the screen and start again.~The second part of each intervention session is the cueing-based reading therapy (READ), which will also last at least 15 minutes. The task of the patient is to read out loud words or a text presented on a paper in front of them. We will use exogenous (e.g., the therapist highlights words when they were omitted) and endogenous cues (verbal instructions which require intrinsic action by the patient) to facilitate attentional shifts to the left. The intensity of cueing will be matched to the actual severity of neglect (adaptive therapy).
Study NCT04273620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optokinetic stimulation and cueing-based reading therapy (OKS-READ)
Description: Each intervention session starts with an optokinetic stimulation (OKS) of at least 15 minutes duration. A pattern of squares, dots, triangles and stars will coherently and continuously move to the left on a computer screen in front of the patients. Patients are instructed to choose one stimulus and follow it with the eyes until it has reached the left side of the screen, then jump to the right edge of the screen and start again.~The second part of each intervention session is the cueing-based reading therapy (READ), which will also last at least 15 minutes. The task of the patient is to read out loud words or a text presented on a paper in front of them. We will use exogenous (e.g., the therapist highlights words when they were omitted) and endogenous cues (verbal instructions which require intrinsic action by the patient) to facilitate attentional shifts to the left. The intensity of cueing will be matched to the actual severity of neglect (adaptive therapy).
Study NCT04273620 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General neuropsychological treatment
Description: As a control treatment the patients will receive neuropsychological treatment without targeting visuospatial attention. Examples for components implemented are supporting conversations, diagnostic assessments (e.g. memory diagnostics) and training of memory and executive functions.
Study NCT04273620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General neuropsychological treatment
Description: As a control treatment the patients will receive neuropsychological treatment without targeting visuospatial attention. Examples for components implemented are supporting conversations, diagnostic assessments (e.g. memory diagnostics) and training of memory and executive functions.
Study NCT03891199 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic-Arm Assisted THA
Description: The study will examine the acetabular cup placement of THA patients and compare results for patients who undergo THA with robotic-arm assistance with those who undergo traditional THA.
Study NCT03379324 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Superiority of augmented repairs
Description: 4cc of FlōGraft® injected into repair subject tissue divided evenly between repair site and muscle body
Study NCT03379324 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fat degeneration of supraspinatus muscle
Description: 4cc of FlōGraft® injected into repair subject tissue divided evenly between repair site and muscle body
Study NCT04335552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care
Study NCT04335552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care
Study NCT04335552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5
Study NCT04335552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5
Study NCT02680951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: 8mg/m2/dose intravenous infusion over 15 minutes, once daily, on days 3 to 5, total 3 doses~Participants with body weight less than 12Kg, the idarubicin dose will be corrected as follows: \[weight (Kg) x dose (per m2)\] divided by 30
Study NCT04073680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serabelisib
Description: Subjects will be dosed with Serabelisib on 3 consecutive days a week in a 28 day cycle until tumor progression. in combination with Canagliflozin 300mg, both are oral medications
Study NCT04073680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300mg
Description: All subjects will be dosed with 300 mg canagliflozin in combination with serabelisib
Study NCT02719028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antroquinonol
Description: Antroquinonol will be provided as capsules of 50 mg
Study NCT02719028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects, however, don't have the active compound(antroquinonol)
Study NCT02719028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects, however, don't have the active compound(antroquinonol)
Study NCT02680951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal (IT) cytarabine
Description: Given intrathecally to all participants on day 1 of course 1 and 2. Omit on day 1 of course 1 if participant received IT therapy within 7 days prior to study enrollment. Intrathecal chemotherapy may be given during the end of course 1 disease evaluation (spinal fluid and bone marrow aspiration) and may be repeated every 7 days with bone marrow evaluations per institutional preference.~Cytarabine dose defined by age:~* 30 mg for patients age 1 - 1.99~* 50 mg for patients age 2 - 2.99~* 70 mg for patients ≥3 years of age~The participant may receive intrathecal triple therapy (ITT) if persistent blasts are present in the cerebral spinal fluid (CSF) based on the treating physician's clinical judgment.
Study NCT01392963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin type A neurotoxin complex
Description: 29-40 U injection
Study NCT01392963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 29-40 U 0.9% NaCl injection
Study NCT02688660 — intervention group
Intervention type: OTHER
Intervention: MRI Scans
Study NCT02289443 — intervention group
Intervention type: OTHER
Intervention: complete denture
Description: Comparison of different procedures
Study NCT01524978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Escalating doses administered on Day 1 and then once weekly by intravenous infusion.
Study NCT01524978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: Escalating doses given orally twice a day starting on Day 2
Study NCT01524978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: 960 mg vemurafenib orally twice a day until disease progression, unacceptable toxicity, or withdrawal of consent.
Study NCT01026220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT01026220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal vincristine sulfate
Description: Given IV
Study NCT01026220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Given IV
Study NCT01026220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT01026220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide phosphate
Description: Given IV
Study NCT01026220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given IV
Study NCT04996459 — intervention group
Intervention type: DRUG
Intervention: Tislelizumab
Description: Tislelizumab 200mg iv q3w
Study NCT01026220 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV or SC
Study NCT01026220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study NCT03762798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Bridge
Description: The Bridge (Also known as NSS-2) is a percutaneous, auricular field stimulator developed to alleviate pain through stimulation of peripheral cranial neurovascular bundles in the external ear that could potentially gain access to brain areas involved in fear, pain and nociception. After five days, the subject will return to the clinic for device removal and disposal.
Study NCT03744520 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Local anesthetic infiltration is applied between the erector spinae muscle fascia and transverse process.
Study NCT03011307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: spinal injection of oxytocin
Study NCT03579173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Infant PFT
Description: Assessed through the raised volume rapid thoracoabdominal compression technique and plethysmography
Study NCT03579173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Clearance Index
Description: The Lung Clearance Index is derived from the Multiple Breath Washout test. It is the cumulative exhaled volume (the volume of gas needed to wash out resident gas mixture out of the lungs) divided by the FRC. The FRC is the amount of air left in the lungs after normal exhalation.
Study NCT03579173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Passive tidal breathing
Description: During quiet sleep, tidal breathing flow-volume curves are obtained. The tPEF/tE is calculated by taking the time it takes to reach peak expiratory flow divided by the total peak expiratory time.
Study NCT02424045 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BCD chemotherapy (Bendamustine, Carboplatin, Dexamethasone)
Description: All patients are scheduled to receive 2 cycles of three-weekly BCD. After 2 cycles of BCD, if the patients with complete remission (CR) or partial remission (PR) would be eligible for autologous stem cell transplantation (ASCT), stem cell collection after 3rd cycle of BCD and high dose chemotherapy and ASCT will be conducted. While ineligible patients to ASCT with non-progressive disease after 2 cycles of BCD, will be given 4 additional courses of the BCD regimen.
Study NCT03650790 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood test
Description: For serum analysis, approximately 2 cc antecubital vein venous blood serum will be taken from each patient to be studied for CTRP9 Level analysis. Adult blood will be centrifuged at 4000 rpm for 10 minutes to separate greenhouses. The obtained serum samples will be stored at -80 ° C until analysis.
Study NCT01555489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: 3x per week
Study NCT00351962 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractionated Stereotactic Radiotherapy
Study NCT01760590 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Manipulation
Description: A grade 5 thrust to the thoracic spine
Study NCT01760590 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mobilization
Description: A grade 1-4 mobilization directed at thoracic spine
Study NCT01344720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoricoxib
Description: At visit 2 eligible patients will then receive Etoricoxib 30mg for 2 weeks. Patients who achieve a clinically meaningful improvement in pain at the end of this period (defined as a ≥30% improvement in BPI avg daily pain intensity), will continue therapy up to week 5 (visit 4), if they become non-responders between week 4-5, they can be tapered off meds and then discontinued from the study. Patients who do not achieve a clinically meaningful improvement will be considered non-responders and will be randomized to receive either titration of their monotherapy or combination treatment.~Group 1 non-responders will receive an increase in monotherapy from etoricoxib 30mg to eterocoxib 60mg/die.
Study NCT01344720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone
Description: At visit 2 eligible patients will then receive Etoricoxib 30mg for 2 weeks. Patients who achieve a clinically meaningful improvement in pain at the end of this period (defined as a ≥30% improvement in BPI avg daily pain intensity), will continue therapy up to week 5 (visit 4), if they become non-responders between week 4-5, they can be tapered off meds and then discontinued from the study. Patients who do not achieve a clinically meaningful improvement will be considered non-responders and will be randomized to receive either titration of their monotherapy or combination treatment.~Group 2 non-responders will receive in addition to etoricoxib 30mg/day a dose of oxycodone CR 5mg q12hr (dose of 5mg tablet is available in Italy).
Study NCT01846650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine tablets
Description: Single oral Capecitabine tablets 2000mg qd
Study NCT01846650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELODA
Description: Single oral XELODA 2000mg qd
Study NCT02562807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS-303 18mg single-dose
Study NCT02562807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAS-303 18mg single-dose
Study NCT02562807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 18mg single-dose
Study NCT02562807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 18mg single-dose
Study NCT02562807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS-303 9mg single-dose
Study NCT02562807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAS-303 9mg single-dose
Study NCT02562807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 9mg single-dose
Study NCT02562807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 9mg single-dose
Study NCT01270256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Pulmicort Respules at a dose of 0.25 mg. delivered intranasally via NasoNeb nebulizer once daily
Study NCT01270256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo delivered intranasally via NasoNeb nebulizer once daily
Study NCT02068872 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy
Description: To assess the safety, tolerability and feasibility of sleeve gastrectomy in the perioperative period following liver transplantation in obese (BMI of > 40 or > 35 kg/m2 in the presence of at least one major obesity related co-morbidities (e.g. type 2 diabetes, hypertension, sleep apnea, heart disease, etc) adult subjects aged 18-75 years of age.